Background: It is a familiar story. A promising multiple sclerosis (MS) treatment clears the
three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost …

Background Multiple sclerosis (MS) is a chronic neurological disorder, which can lead to a
wide range of disabling symptoms. The condition has a significant negative impact on health …

OBJECTIVE: To derive robust estimates for the cost of multiple sclerosis (MS) based on a
variety of cost factors across a number of different cost perspectives. This is essential to …

This article compares the findings of several evaluation studies undertaken to assess the
economic cost and burden of multiple sclerosis (MS) therapies, and discusses issues for …

Multiple sclerosis (MS) is one of the most common causes of neurological disability in young
and middle-aged adults. The full economic cost of MS is substantial given that MS patients …

Abstract Background Economic costs of Multiple Sclerosis (MS) in Australia were last
estimated in 2010 and are likely to have changed over time, especially given this new era of …

The growing number of disease-modifying treatments (DMTs) for patients with multiple
sclerosis (MS) and the high acquisition costs of these DMTs are likely to increase the …

The overall burden of neurological disease on society is considerable and complex with
individual effects on social functions, employment and health care provision as well as …

Background: Multiple sclerosis (MS) is an important, highly disabling neurological disease,
common among young adults in The Netherlands. Nevertheless, only a few studies to date …

Multiple sclerosis (MS) is a leading cause of disability among young adults and has a
significant economic impact on society. Although MS is not currently a curable disease …